Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients

References

• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• Mukai N, Doi Y, Ninomiya T, et al. Trends in the prevalence of type 2 diabetes and prediabetes in community-dwelling Japanese subjects: the Hisayama study. J Diabetes Investig 2014;5:162-9
   PubMed Web of Science ®Google Scholar
• Kitamura A, Nagano E, Uno M, et al. P2-143 trends in the prevalence of diabetes and diabetic retinopathy among Japanese urban population. J Epidemiol Community Health 2011;65:A260
   Google Scholar
• Charvat H, Goto A, Goto M, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig 2015;6:533-42
   PubMed Web of Science ®Google Scholar
• Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference. Clin Med Insights Endocrinol Diabetes 2011;4:47-62
   PubMedGoogle Scholar
• Salanti G, Higgins JPT, Ades AE, Ioannidis JPA. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Statistical Assoc 2006;101:447-59
   Web of Science ®Google Scholar
• Jansen JP, Cappelleri JC, Fleurence R, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Mills EJ, Ioannidis JP, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308:1246-53
   PubMed Web of Science ®Google Scholar
• Kanters S, Ford N, Druyts E, et al. Use of network meta-analysis in clinical guidelines. Bull World Health Organ 2016;94:782-4
   PubMed Web of Science ®Google Scholar
• Stregenga H, Rogers G, Kandaswamy P, Jones D. Network Meta-Analyses in National Clinical Guidelines: A Description and Quality Assessment, Berlin. Guidelines International Network, 2012
   Google Scholar
• Dias S, Welton N, Sutton A, Ades A. Technical Support Document 2: A Generalized Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomized Controlled Trials. National Institute for Health and Clinical Excellence, 2011
   Google Scholar
• Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester: John Wiley & Sons, 2004
   Google Scholar
• Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010;12:341-7
   PubMed Web of Science ®Google Scholar
• Miyagawa J, Odawara M, Takamura T, et al. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab 2015;17:974-83
   PubMed Web of Science ®Google Scholar
• Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;81:161-8
   PubMed Web of Science ®Google Scholar
• Suzuki K, Tanaka S, Aoki C, et al. Greater efficacy and improved endothelial dysfunction in untreated type 2 diabetes with liraglutide versus sitagliptin. Dokkyo J Med Sci 2014;41:211-20
   Google Scholar
• Takamura T, Miygawa J-I, Odawara M, et al. Efficacy and safety of once-weekly dulaglutide vs. once-daily liraglutide in Japanese patients with type 2 diabetes. American Diabetes Association 75th scientific sessions, 5–9 June 2015
   Google Scholar
• Takeshita Y, Takamura T, Kita Y, et al. Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: a randomized, parallel-group study. J Diabetes Investig 2015;6:192-200
   PubMed Web of Science ®Google Scholar
• Tanaka K, Saisho Y, Kawai T, et al. Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. Endocrine J 2015;62:399-409
   PubMed Web of Science ®Google Scholar
• Gantz I, Okamoto T, Ito Y, et al. Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial. Diabetologia 2014;1:S55
   Google Scholar
• Kadowaki T, Tajima N, Odawara M, et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetology Int 2013;4:160-72
   Google Scholar
• Kadowaki T, Tajima N, Odawara M, et al. Addition of sitagliptin, an oral, highly-selective dipeptidyl peptidase-4 inhibitor, improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetes 2011;60:A279-80
   Web of Science ®Google Scholar
• Kadowaki T, Tajima N, Odawara M, et al. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. J Diabetes Investig 2013;4:174-81
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Kadowaki T, Tajima N, et al. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes. J Diabetes Investig 2011;2:381-90
   PubMed Web of Science ®Google Scholar
• Ohira M, Yamaguchi T, Saiki A, et al. Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus. Clin Investig Med 2014;37:E243-51
   PubMed Web of Science ®Google Scholar
• Otsuka Y, Yamaguchi S, Furukawa A, et al. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Endocrine J 2015;62:133-43
   PubMed Web of Science ®Google Scholar
• Satoh-Asahara N, Sasaki Y, Wada H, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013;62:347-51
   PubMed Web of Science ®Google Scholar
• Tajima N, Kadowaki T, Okamoto T, et al. Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. J Diabetes Investig 2013;4:595-604
   PubMed Web of Science ®Google Scholar
• Tajima N, Kadowaki T, Odawara M, et al. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetology Int 2011;2:32-44
   Google Scholar
• He YL, Yamaguchi M, Ito H, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Therapeut 2010;48:582-95
   PubMed Web of Science ®Google Scholar
• Hirose T, Suzuki M, Tsumiyama I. Efficacy and safety of vildagliptin as an add-on to insulin with or without metformin in Japanese patients with type 2 diabetes mellitus: A 12-week, double-blind, randomized study. Diabetes Ther 2015;6:559-71
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Abe N, Kato M, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009;83:233-40
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010;89:216-23
   PubMed Web of Science ®Google Scholar
• Odawara M, Hamada I, Suzuki M. Efficacy and safety of vildagliptin as add-on to metformin in Japanese patients with type 2 diabetes mellitus. Diabetes Ther 2014;5:169-81
   PubMed Web of Science ®Google Scholar
• Tani S, Takahashi A, Nagao K, Hirayama A. Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus. Am J Cardiol 2015;115:454-60
   PubMed Web of Science ®Google Scholar
• Inagaki N, Onouchi H, Maezawa H, et al. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol 2015;3:191-7
   PubMed Web of Science ®Google Scholar
• Kaku K, Itayasu T, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab 2011;13:1028-35
   PubMed Web of Science ®Google Scholar
• Kaku K, Mori M, Kanoo T, et al. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother 2014;15:2121-30
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 2011;27(Suppl3):21-9
   Web of Science ®Google Scholar
• Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab 2012;14:927-36
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 2011;27:1781-92
   Google Scholar
• Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012;14:1040-6
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy, safety and dose–response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:810-18
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2013;4:576-84
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 2014;16:418-25
   PubMed Web of Science ®Google Scholar
• Inagaki N, Watada H, Murai M, et al. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15:833-43
   PubMed Web of Science ®Google Scholar
• Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012;14:348-57
   PubMed Web of Science ®Google Scholar
• Gantz I, Okamoto T, Sato A, et al. Omarigliptin improves glycemic control and is well tolerated as add-on therapy to oral antihyperglycemic agents in Japanese patients with type 2 diabetes. Diabetes 2015;64:A318-19
   Web of Science ®Google Scholar
• Inagaki N, Onouchi H, Sano H, et al. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:125-32
   PubMed Web of Science ®Google Scholar
• Hirose T, Tsumiyama I, Suzuki M. Efficacy and safety of vildagliptin as add-on to insulin, with or without metformin, in Japanese patients with T2DM World Diabetes Congress, 30 November–4 December 2015
   Google Scholar
• Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocrine J 2014;61:949-59
   PubMed Web of Science ®Google Scholar
• Nikolakopoulou A, Chaimani A, Veroniki AA, et al. Characteristics of networks of interventions: a description of a database of 186 published networks. PLoS One 2014;9:e86754
   PubMed Web of Science ®Google Scholar
• Fahrbach JL, Fu H, Shurzinske L, et al. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg. Int J Clin Pract 2016;70:218-21
   PubMed Web of Science ®Google Scholar
• Kayaniyil S, Lozano-Ortega G, Bennett HA, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. Diabetes Ther 2016;7:27-43
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Quan X, et al. Efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists among type 2 diabetes: a systematic review and network meta-analysis. PLoS One 2016;11:e0154206
   PubMed Web of Science ®Google Scholar
• Lorenzi M, Ploug UJ, Vega G, Jansen JP. Liraglutide vs other daily GLP-1 analogues in people with type 2 diabetes: a network meta-analysis. Value Health 2015;18:A598-9
   PubMed Web of Science ®Google Scholar
• Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 2015;110:26-37
   PubMed Web of Science ®Google Scholar
• Ito D, Iuchi T, Kurihara S, et al. Efficacy and clinical characteristics of liraglutide in Japanese patients with type 2 diabetes. J Clin Med Res 2015;7:694-9
   PubMedGoogle Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28
   PubMed Web of Science ®Google Scholar
• Buse JB, Poulter N, Zinman B, et al. Results of the Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcome Results (LEADER) Trial. American Diabetes Association 76th scientific sessions, 10–14 June 2016
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The Japan Diabetes Society. Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013. Available at: http://www.jds.or.jp/modules/en/index.php?content_id =44 [Last accessed 11 December 2016]
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Calvo Gomez C, Gomez-Huelgas R, Lima Ruiz J, et al. Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine. Int J Clin Pharmacol Ther 2016;54:880-90
   PubMed Web of Science ®Google Scholar
• Ishii H, Niiya T, Ono Y, et al. Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study. Diabetology & Metabolic Syndrome 2017;9:3
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013;4:190-201
   PubMedGoogle Scholar
• von Scholten BJ, Hansen TW, Goetze JP, et al. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications 2015;29:670-4
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bain SC, Atkin SL, et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 2016;39:222-30
   PubMed Web of Science ®Google Scholar